Acrivon Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress

 Initial ACR-368 Phase 2b clinical data in patients with ovarian or endometrial cancers (n=26; 10 OncoSignature-positive and 16 OncoSignature-negative) are being presented

•  A 50% confirmed overall response rate observed with ACR-368 in OncoSignature-positive gynecological (ovarian and endometrial) cancers
•  Initial clinical validation of AP3 patient selection platform, demonstrated ability to prospectively predict ACR-368 RECIST responders (p-value = 0.0038)
•  ACR-2316, a potential first-in-class dual WEE1/PKMYT1 inhibitor, IND timeline accelerated with filing now expected in Q3 2024
•  Acrivon hosts Corporate R&D event webcast today at 4:15 pm ET

A live and recorded webcast of the event will be available through a link on the Events & Presentations page within the investor section of the company’s website at https://ir.acrivon.com/news-events/events-presentations. The webcast will be available for at least 30 days following the event.

https://www.globenewswire.com/news-release/2024/04/24/2869048/0/en/Acrivon-Therapeutics-Reports-Initial-Positive-Clinical-Data-for-ACR-368-and-Pipeline-Program-Progress-Today-at-Corporate-R-D-Event.html